Manika Kaul

1.8k total citations · 1 hit paper
10 papers, 416 citations indexed

About

Manika Kaul is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Infectious Diseases. According to data from OpenAlex, Manika Kaul has authored 10 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 1 paper in Infectious Diseases. Recurrent topics in Manika Kaul's work include Lung Cancer Treatments and Mutations (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Advanced Breast Cancer Therapies (2 papers). Manika Kaul is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Advanced Breast Cancer Therapies (2 papers). Manika Kaul collaborates with scholars based in United States, Germany and Japan. Manika Kaul's co-authors include Carlos H. Barrios, Eric P. Winer, Véronique Dièras, Andreas Schneeweiß, Shilpen Patel, Luciana Molinero, A. Swat, Hiroji Iwata, Sherene Loi and Leisha A. Emens and has published in prestigious journals such as Annals of Oncology, Thorax and Journal of Thoracic Oncology.

In The Last Decade

Manika Kaul

9 papers receiving 409 citations

Hit Papers

First-line atezolizumab plus nab-paclitaxel for unresecta... 2021 2026 2022 2024 2021 50 100 150 200 250

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Manika Kaul United States 5 333 169 114 93 48 10 416
Laura Iezzi Italy 11 308 0.9× 79 0.5× 102 0.9× 84 0.9× 76 1.6× 21 411
Khalid Jazieh United States 9 173 0.5× 102 0.6× 32 0.3× 48 0.5× 54 1.1× 24 285
Myriam Delaunay France 9 368 1.1× 221 1.3× 204 1.8× 87 0.9× 48 1.0× 13 443
Claire Tissot France 10 208 0.6× 261 1.5× 134 1.2× 19 0.2× 107 2.2× 22 394
Denisse Bretel Peru 6 165 0.5× 108 0.6× 78 0.7× 76 0.8× 89 1.9× 6 306
Magdalena Skórzewska Poland 12 130 0.4× 143 0.8× 49 0.4× 18 0.2× 47 1.0× 34 329
Débora S. Bruno United States 12 215 0.6× 128 0.8× 82 0.7× 77 0.8× 51 1.1× 45 352
Mara A. Cafferata Italy 10 195 0.6× 243 1.4× 39 0.3× 21 0.2× 68 1.4× 23 399
John M. Richart United States 8 154 0.5× 59 0.3× 23 0.2× 109 1.2× 68 1.4× 21 280
Margherita Ambrosini Italy 11 242 0.7× 65 0.4× 51 0.4× 51 0.5× 35 0.7× 25 301

Countries citing papers authored by Manika Kaul

Since Specialization
Citations

This map shows the geographic impact of Manika Kaul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manika Kaul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manika Kaul more than expected).

Fields of papers citing papers by Manika Kaul

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manika Kaul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manika Kaul. The network helps show where Manika Kaul may publish in the future.

Co-authorship network of co-authors of Manika Kaul

This figure shows the co-authorship network connecting the top 25 collaborators of Manika Kaul. A scholar is included among the top collaborators of Manika Kaul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manika Kaul. Manika Kaul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Kim, Tae Min, Charles Ricordel, Jhanelle E. Gray, et al.. (2024). 1302P MET×MET bispecific antibody davutamig (REGN5093) for MET-altered advanced non-small cell lung cancer (aNSCLC): Update from a first-in-human (FIH) study. Annals of Oncology. 35. S828–S829. 2 indexed citations
2.
Makharadze, Tamta, Miranda Gogishvili, Tamar Melkadze, et al.. (2024). Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial. Lung Cancer. 193. 107821–107821. 4 indexed citations
4.
Makharadze, Tamta, Miranda Gogishvili, Tamar Melkadze, et al.. (2023). Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial. Journal of Thoracic Oncology. 18(6). 755–768. 39 indexed citations
5.
Emens, Leisha A., Sylvia Adams, Carlos H. Barrios, et al.. (2021). First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Annals of Oncology. 32(8). 983–993. 293 indexed citations breakdown →
7.
Bader, Klaus, et al.. (2017). Entwicklung bodengebundener Notarzteinsätze im Stadtgebiet Leipzig von 2003 bis 2013. Der Anaesthesist. 67(3). 177–187. 20 indexed citations
9.
Stöger, Herbert, Thomas Bauernhofer, Michael C. Schmid, et al.. (1990). Combination Therapy of 4′-O-Tetrahydropyranyl-Doxorubicin, 5-Fluorouracil, and High-Dose Folinic Acid in Patients with Advanced Breast Cancer. American Journal of Clinical Oncology. 13. S44–47. 4 indexed citations
10.
Kaul, Manika, et al.. (1980). Decreased Gut‐associated IgA Levels in Patients with Typhoid Fever. Scandinavian Journal of Immunology. 11(6). 623–628. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026